Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Wasted Anti-Cancer Agents Due to Cancellations after Dispensing].
Fukuda M, Honda T, Uchida T, Nose S, Kodama Y, Hashizume J, Tsuchiya A, Matsuo K, Kamada M, Honda K, Ishii K, Yamaguchi H, Mukae H, Ashizawa K. Fukuda M, et al. Among authors: yamaguchi h. Gan To Kagaku Ryoho. 2022 Aug;49(8):861-865. Gan To Kagaku Ryoho. 2022. PMID: 36046971 Japanese.
[Trends in Outpatient Chemotherapy for Thoracic Oncology].
Fukuda M, Yamaguchi H, Takemoto S, Senju H, Gyotoku H, Dotsu Y, Umeyama Y, Tsuchiya A, Ikeda T, Nose S, Honda T, Kobayashi K, Ishii K, Mukae H, Ashizawa K. Fukuda M, et al. Among authors: yamaguchi h. Gan To Kagaku Ryoho. 2020 Oct;47(10):1461-1464. Gan To Kagaku Ryoho. 2020. PMID: 33130741 Japanese.
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M, Yamaguchi H, Fukuda M, Tomono H, Honda N, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Takemoto S, Ikeda T, Nakatomi K, Nakamura Y, Nagashima S, Yamazaki T, Mukae H. Shimada M, et al. Among authors: yamaguchi h. Cancer Chemother Pharmacol. 2019 Nov;84(5):1059-1064. doi: 10.1007/s00280-019-03940-0. Epub 2019 Sep 5. Cancer Chemother Pharmacol. 2019. PMID: 31486872 Clinical Trial.
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: yamaguchi h. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H. Takemoto S, et al. Among authors: yamaguchi h. Thorac Cancer. 2017 Nov;8(6):577-581. doi: 10.1111/1759-7714.12483. Epub 2017 Aug 3. Thorac Cancer. 2017. PMID: 28771961 Free PMC article. Clinical Trial.
Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation.
Dotsu Y, Fukuda M, Honda N, Gyotoku H, Kohno Y, Suyama T, Umeyama Y, Taniguchi H, Takemoto S, Yamaguchi H, Miyazaki T, Sakamoto N, Obase Y, Ikeda H, Ashizawa K, Mukae H. Dotsu Y, et al. Among authors: yamaguchi h. Thorac Cancer. 2021 Jan;12(2):272-276. doi: 10.1111/1759-7714.13756. Epub 2020 Nov 20. Thorac Cancer. 2021. PMID: 33215864 Free PMC article.
4,908 results